ARTICLE | Product Development
AbbVie’s miss in cystic fibrosis extends lead for Vertex’s Trikafta
With triple combo failing to meet efficacy threshold, AbbVie aims to test a different triplet for CF
April 29, 2022 11:21 PM UTC
The failure of AbbVie’s cystic fibrosis triplet to meet a clinical efficacy threshold for advancement will leave the pharma further behind Vertex as it seeks to develop a competitor to blockbuster Trikafta/Kaftrio, driving a 10-digit shift in market cap Friday.
During its 1Q22 earnings call, AbbVie Inc. (NYSE:ABBV) revealed that a combination including C2 corrector ABBV-119 fell short of its prespecified criteria in a Phase II proof-of-concept study...
BCIQ Target Profiles